Zan Hou1, Guangjun Li, Sen Bai. 1. West China Hospital Cancer Center, Sichuan University, Chengdu, People's Republic of China.
Abstract
PURPOSE: To assess the efficacy and toxicity between high-dose radiotherapy (HDRT) and conventional-dose radiotherapy (CDRT) by collecting randomized controlled trials of long-term follow-ups. METHODS: Unrestricted by language, we searched Ovid MEDLINE, Ovid EMBASE, Cochrane Library, Science Citation Index (Web of Science) and ClinicalTrials.gov for the following end points: biochemical failure (BF), overall survival (OS), prostate cancer-specific survival (PCSS) and side effects. The meta-analysis was performed by using Review Manager 5.2 and Stata version 12.0 software packages. Results were expressed as the odds ratio (OR) with the corresponding 95 % confidence interval (CI). RESULTS: Six randomized controlled trials, with a total population of 2,822, were eligible. In terms of 10-year efficacy relative to CDRT, the HDRT was associated with almost an equivalent OS (73.4 vs. 74.3 %, OR 1.05, 95 % CI 0.86-1.28; p = 0.64) and PCSS (90.7 vs. 91.6 %, OR 1.11, 95 % CI 0.83-1.49; p = 0.47), but a significant decrease in the BF (34.0 vs. 24.7 %, OR 0.61, 95 % CI 0.51-0.74; p < 0.00001). In terms of toxicity, HDRT significantly increased the late Grade 2 or higher (G ≥ 2) gastrointestinal toxicity (28.0 vs. 18.6 %, OR 1.72, 95 % CI 1.42-2.08; p < 0.00001) and late G ≥ 2 genitourinary (GU) toxicity (22.6 vs. 19.5 %, OR 1.24, 95 % CI 1.01-1.52; p = 0.04). In the subgroup analysis, trials with or without androgen deprivation therapy both had a significant decrease in the BF at 10 years. With regard to quality of life, there was no significant difference between HDRT and CDRT (p > 0.05). CONCLUSION: This was the first meta-analysis of trials with long-term follow-up to indicate that HDRT is superior to CDRT in terms of preventing BF in localized prostate cancer patients. However, this advantage did not translate into an improvement in OS and PCSS. This was also the first meta-analysis to suggest that the HDRT in three-dimensional conformal radiotherapy (3D-CRT) significantly increases the late G ≥ 2 GU toxicity. Thus, the dose escalation in 3D-CRT should be discreetly used in the treatment of prostate cancer due to the increase in late toxicities.
PURPOSE: To assess the efficacy and toxicity between high-dose radiotherapy (HDRT) and conventional-dose radiotherapy (CDRT) by collecting randomized controlled trials of long-term follow-ups. METHODS: Unrestricted by language, we searched Ovid MEDLINE, Ovid EMBASE, Cochrane Library, Science Citation Index (Web of Science) and ClinicalTrials.gov for the following end points: biochemical failure (BF), overall survival (OS), prostate cancer-specific survival (PCSS) and side effects. The meta-analysis was performed by using Review Manager 5.2 and Stata version 12.0 software packages. Results were expressed as the odds ratio (OR) with the corresponding 95 % confidence interval (CI). RESULTS: Six randomized controlled trials, with a total population of 2,822, were eligible. In terms of 10-year efficacy relative to CDRT, the HDRT was associated with almost an equivalent OS (73.4 vs. 74.3 %, OR 1.05, 95 % CI 0.86-1.28; p = 0.64) and PCSS (90.7 vs. 91.6 %, OR 1.11, 95 % CI 0.83-1.49; p = 0.47), but a significant decrease in the BF (34.0 vs. 24.7 %, OR 0.61, 95 % CI 0.51-0.74; p < 0.00001). In terms of toxicity, HDRT significantly increased the late Grade 2 or higher (G ≥ 2) gastrointestinal toxicity (28.0 vs. 18.6 %, OR 1.72, 95 % CI 1.42-2.08; p < 0.00001) and late G ≥ 2 genitourinary (GU) toxicity (22.6 vs. 19.5 %, OR 1.24, 95 % CI 1.01-1.52; p = 0.04). In the subgroup analysis, trials with or without androgen deprivation therapy both had a significant decrease in the BF at 10 years. With regard to quality of life, there was no significant difference between HDRT and CDRT (p > 0.05). CONCLUSION: This was the first meta-analysis of trials with long-term follow-up to indicate that HDRT is superior to CDRT in terms of preventing BF in localized prostate cancerpatients. However, this advantage did not translate into an improvement in OS and PCSS. This was also the first meta-analysis to suggest that the HDRT in three-dimensional conformal radiotherapy (3D-CRT) significantly increases the late G ≥ 2 GU toxicity. Thus, the dose escalation in 3D-CRT should be discreetly used in the treatment of prostate cancer due to the increase in late toxicities.
Authors: David J D'Ambrosio; Alan Pollack; Eleanor E R Harris; Robert A Price; Lynn J Verhey; Mack Roach; D Jeffrey Demanes; Michael L Steinberg; Louis Potters; Paul E Wallner; Andre Konski Journal: Int J Radiat Oncol Biol Phys Date: 2008-03-01 Impact factor: 7.038
Authors: Jeff Michalski; Kathryn Winter; Mack Roach; Arnold Markoe; Howard M Sandler; Janice Ryu; Matthew Parliament; James A Purdy; Richard K Valicenti; James D Cox Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-01 Impact factor: 7.038
Authors: Anthony L Zietman; Kyounghwa Bae; Jerry D Slater; William U Shipley; Jason A Efstathiou; John J Coen; David A Bush; Margie Lunt; Daphna Y Spiegel; Rafi Skowronski; B Rodney Jabola; Carl J Rossi Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Abrahim Al-Mamgani; Wim L J van Putten; Wilma D Heemsbergen; Geert J L H van Leenders; Annerie Slot; Michel F H Dielwart; Luca Incrocci; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2008-05-19 Impact factor: 7.038
Authors: Wilma D Heemsbergen; Abrahim Al-Mamgani; Annerie Slot; Michel F H Dielwart; Joos V Lebesque Journal: Radiother Oncol Date: 2013-11-15 Impact factor: 6.280
Authors: David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Oncol Date: 2014-02-26 Impact factor: 41.316
Authors: Mirko Nitsche; Werner Brannath; Matthias Brückner; Dirk Wagner; Alexander Kaltenborn; Nils Temme; Robert M Hermann Journal: Br J Radiol Date: 2016-12-12 Impact factor: 3.039
Authors: Eva K Sage; Thomas E Schmid; Hans Geinitz; Mathias Gehrmann; Michael Sedelmayr; Marciana N Duma; Stephanie E Combs; Gabriele Multhoff Journal: Strahlenther Onkol Date: 2017-05-12 Impact factor: 3.621
Authors: Miguel Reis Ferreira; Atia Khan; Karen Thomas; Lesley Truelove; Helen McNair; Annie Gao; Chris C Parker; Robert Huddart; Margaret Bidmead; Ros Eeles; Vincent Khoo; Nicholas J van As; Vibeke N Hansen; David P Dearnaley Journal: Int J Radiat Oncol Biol Phys Date: 2017-08-02 Impact factor: 7.038
Authors: David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall Journal: Lancet Oncol Date: 2016-06-20 Impact factor: 41.316